Eugene Seymour, CEO, further added, We believe that our business plan is sound. Actual events could differ materially and substantially from those projected herein and depend on number of factors including the success of the Companys research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.. NanoViricideTM is specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to specific type of virus, like guided missile. Dr.

NanoViricide drugs are designed to block and dismantle the virus particles before they can infect cell, thereby controlling viremia. is development stage company that is creating special purpose nanomaterials for viral therapy. Dr. NanoViricideTM is specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to specific type of virus, like guided missile.

Dr. is development stage company that is creating special purpose nanomaterials for viral therapy. Actual events could differ materially and substantially from those projected herein and depend on number of factors including the success of the Companys research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.. NanoViricideTM is specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to specific type of virus, like guided missile.

Actual events could differ materially and substantially from those projected herein and depend on number of factors including the success of the Companys research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.. We have strong drug pipeline with industryleading drugs against highly pathogenic bird flu and common influenza in preclinical studies, and an antirabies drug in development. This press release contains forwardlooking statements that reflect the Companys current expectation regarding future events. Dr Seymour continued, NanoViricides at this time is strong.